Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
Go back to Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec| CytoDyn, Inc. (AMEX: CYDY) | Delayed: 0.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.24 | 52 Week High | $1.57 | |||
| Open | $0.25 | 52 Week Low | $0.61 | |||
| Day High | $0.26 | P/E | N/A | |||
| Day Low | $0.22 | EPS | $0.00 | |||
| Volume | 3,180,488 | |||||
